United Therapeutics Co. (NASDAQ:UTHR) CFO Sells $2,773,016.96 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CFO James Edgemond sold 7,792 shares of the stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $355.88, for a total transaction of $2,773,016.96. Following the completion of the transaction, the chief financial officer now owns 5,884 shares in the company, valued at $2,093,997.92. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

James Edgemond also recently made the following trade(s):

• On Monday, October 7th, James Edgemond sold 7,794 shares of United Therapeutics stock. The shares were sold at an average price of $355.54, for a total transaction of $2,771,078.76.
• On Monday, September 30th, James Edgemond sold 7,792 shares of United Therapeutics stock. The stock was sold at an average price of $358.62, for a total value of $2,794,367.04.
• On Monday, September 23rd, James Edgemond sold 7,796 shares of United Therapeutics stock. The stock was sold at an average price of $354.04, for a total value of $2,760,095.84.
• On Monday, September 9th, James Edgemond sold 7,802 shares of United Therapeutics stock. The shares were sold at an average price of $345.41, for a total transaction of $2,694,888.82.
• On Tuesday, September 3rd, James Edgemond sold 7,785 shares of United Therapeutics stock. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45.

United Therapeutics Stock Performance

United Therapeutics stock opened at $372.81 on Friday. The stock has a fifty day moving average price of $349.90 and a 200 day moving average price of $306.93. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $377.03. The firm has a market capitalization of $16.54 billion, a P/E ratio of 17.63, a PEG ratio of 1.30 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). The company had revenue of $714.90 million during the quarter, compared to analysts’ expectations of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. United Therapeutics’s revenue for the quarter was up 19.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.24 earnings per share. Equities research analysts anticipate that United Therapeutics Co. will post 24.72 earnings per share for the current year.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of UTHR. ClariVest Asset Management LLC boosted its position in United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 42 shares during the period. V Square Quantitative Management LLC purchased a new stake in shares of United Therapeutics during the second quarter worth about $30,000. Rise Advisors LLC purchased a new position in United Therapeutics in the first quarter valued at about $32,000. Innealta Capital LLC acquired a new stake in United Therapeutics during the 2nd quarter valued at approximately $33,000. Finally, USA Financial Formulas purchased a new stake in United Therapeutics during the 3rd quarter worth approximately $33,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have commented on UTHR shares. HC Wainwright reaffirmed a “buy” rating and set a $400.00 price objective on shares of United Therapeutics in a research note on Thursday, August 1st. Oppenheimer lifted their target price on shares of United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a report on Wednesday, August 28th. Bank of America lowered their price objective on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a report on Thursday, August 1st. LADENBURG THALM/SH SH downgraded United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Morgan Stanley lowered United Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price objective for the stock from $310.00 to $321.00 in a report on Thursday, July 11th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $357.17.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.